Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Corporate Update (June 2017)

22 slides from Windtree Therapeutics's corporate update, Jun 30, 2017

  1. Slide 1: Investor Conference Call: AEROSURF Phase 2b Update

    Se a) WINDTREE Investor Conference Call AEROSURF® Phase 2b Update June 29, 2017 OTCQB:WINT

  2. Slide 2: Forward-looking Statement

    Forward-looking Statement To the extent that statements in this presentation are not strictly historical, including statements about the Company’s clinical development programs, business strategy, outlook, objectives, plans, intentions, goals, future financial conditions, future collaboration agreem

  3. Slide 3: AEROSURF Phase 2 Program Components

    AEROSURF” Phase 2 Program Components Study / Activity Rationale / Objective Status Phase 2a _Initial safety & tolerability (29-34 wk gestational age (GA) Completed 2a Expansion _Extending the dose rangein 29-34 wk GA Completed Phase2a _ Safety and tolerability in 26-28 wk GA Completed Phase2b 28-32

  4. Slide 4: AEROSURF Phase 2b in Premature Infants 28-32 Week GA

    AEROSURF® Phase 2b in Premature Infants 28-32 Week GA

  5. Slide 5: AEROSURF Phase 2b Study: Trial Objectives

    AEROSURF” Phase 2b Study (28 to 32 wk GA) Trial Objectives * Evaluate safety and tolerability * Demonstrate efficacy * Determine effect size for phase 3 planning * Dose(s) selection for phase 3 (or additional phase 2 confirmation) * Evaluate performance of our phase 2 prototype device

  6. Slide 6: AEROSURF Phase 2b Study design

    AEROSURF” Phase 2b Study (28 to 32 wk GA) * 3 dose groups: v¥25 minute (40 mg/kg) (with up to 2 repeat doses) v¥50 minute doses (80 mg/kg) (with up to 2 repeat doses) ¥ Control (nCPAP alone) * Primary endpoint: nCPAP failure (defined as the need for intubation and delayed surfactant) * Up to 240 pat

  7. Slide 7: AEROSURF Phase 2b Study Patients Enrolled

    AEROSURF” Phase 2b Study (28 to 32 wk GA) 221 Patients Enrolled 50 sites participated: 92 oF Eneollinent °US 19 * Canada * Poland * Netherlands 4. North 8 1. * Hungary 6 2 zh 3 America m@LATAM * Ireland mEU * Chile * Colombia S@ winptREe oe nee 7

  8. Slide 8: AEROSURF Phase 2b Clinical Highlights

    AEROSURF® Phase 2b Clinical Highlights = The planned top line analysis of the primary endpoint did not show a treatment effect = Excluding the impact of treatment interruptions, the 50 minute dose achieved a positive treatment effect on the upside of our target and replicates the results in our 2a s

  9. Slide 9: Incidence of nCPAP Failure at 72 Hours

    Incidence of nCPAP Failure at 72 Hours mITT, All Patients receiving Study Treatment INDTREE 30% 20% 10% 44% 4% 44% nCPAP Only 40 mg/kg 80 mg/kg (N=71) (25min) (50min) (N=71) (N=72)

  10. Slide 10: Time to nCPAP Failure (from birth)

    Time to nCPAP Failure (from birth) mITT, All Patients receiving Study Treatment ‘Aerosurt Winatree Therapeutics.Inc. Protocol 03-CL-1202 Date 06/24/2017 Time until Intubation Modified Intent-to-Treat Population 1.00 0.90 ° 8 0.70 Subjects nat intubated (%) 0.60 0.00 12.0 24.0 36.0 48.0 60.0 72.0 Hou

  11. Slide 11: Treatment Interruption Overview

    Treatment Interruption Overview = Treatment interruptions occur after aerosol delivery begins and is then stopped prior to completion of the specified time/dose = Phase 2a Study - Open Label (80 patients) * Only ~5% of doses were interrupted and did not impact results = Phase 2b - Blinded study (221

  12. Slide 12: Clinical Management of Treatment Interruptions

    Clinical Management of Treatment Interruptions 1. Confirmed this was a non-safety related issue * Device worked as designed to shut down treatment upon sensing back pressure due to clogged filter (which occurs at the machine and does not affect the patient) * Data Safety Monitoring Board (and Steeri

  13. Slide 13: nCPAP Failure Rate Over Time by Treatment Group

    nCPAP Failure Rate Over Time by Treatment Group Percent of Subjects who Failed by Treatment by Study Enrollment 100% 90% aon | 7% z Fi 60% bn cs 2 40% 2 = sox 20% 10% o% * . ° 10 20 30 40 so 60 70 20 —ncrar —apme/e —s9mn SRw. Bin ‘Bin ae B

  14. Slide 14: 80 mg/kg (50 min) Treatment Interruptions and nCPAP Failures Over Time

    80 mg/kg (50 min) Treatment Interruptions and nCPAP Failures Over Time Treatment Interruption Rate: ercentage of Enrollments with Treatment Interruption 3/21/2016 5/10/2016 6/29/2016 B/18/2016 107776 U/RSAOI 1/5/2017 3/6/2017 4/25/2017 6/14/2017 INDTREE oy

  15. Slide 15: Time to nCPAP Failure (from birth)

    Time to nCPAP Failure (from birth) mITT Without Treatment Interruptions ‘Aerosurt Windtree Therapeutics.inc. Protocol 03-CL-1202 Date 06/27/2017 Time until Intubation Modified Intent-to-Treat Population Without Device Related Interruptions os} = = 3 gore — Ba ane) + + + + 4 is ene — somgfegt25 in} (

  16. Slide 16: Incidence of nCPAP Failure

    Incidence of nCPAP Failure mITT Without Treatment Interruptions a 44% = 31% nCPAP Only 40 mg/kg 80 mg/kg (N=71) (25min) (50 min) (N=65) (N=45) AEROSURF® treated patients in the 50 min dose group without treatment interruptions experienced a 13% absolute reduction or a 30% relative reduction in nCPAP

  17. Slide 17: Incidence of nCPAP Failure Across the Two Highest Enrolling Countries

    Incidence of nCPAP Failure Across the Two Highest Enrolling Countries (m/TT ) Higher treatment interruptions (higher impaired filter lots) Lower treatment interruptions (no impaired filter lots) Poland jum us eo 60% ooo — 50% 50% ay y ‘0% 38% a ll 30% 20% 1 23 24 aie 20 23 + 0% nCPAP Only 40 mg/kg 8

  18. Slide 18: Respiratory Support in Patients Who Failed nCPAP

    Respiratory Support in Patients Who Failed nCPAP Respiratory Support Durations Mean Values by Treatment and Types of Respiratory Support 10 J 120 a0 39) ae % mncore o ° 20 a J Mecha Venttion SuplementalOnyen In patients who failed CPAP and required intubation and mechanical ventilation, AEROSURF tre

  19. Slide 19: Time On Mechanical Ventilation and Supplemental Oxygen

    Time On Mechanical Ventilation and Supplemental Oxygen FiO, While Receiving Mechanical Ventilation Safety Population Dayi- Osy2- Oay2- Day3- Oay3- Day Day4- DayS- OayS- Day6- Oay6- Day?- Oay7- 20:00 08:00 20:00 08:00 20:00 08:00 20:00 08:00 20:00 08:00 20:00 08:00 20:00 Study Day/Time —tasomalke —-B

  20. Slide 20: Safety & Tolerability Profile

    Safety & Tolerability Profile = The adverse event and serious adverse event profile was similar across the 3 groups = Complications of prematurity were also similar 40 mg/kg 80 mg/kg nCPAP Only (25 min) (50 min) Acquired Sepsis 13 (19%) 14 (20%) 16 (25%) Air Leak 7 (10%) 7 (10%) 9 (14%) Apnea 31 (45

  21. Slide 21: AEROSURF Phase 2b Summary

    AEROSURF® Phase 2b Summary The planned top line analysis of the primary endpoint did not show a treatment effect When dosed as intended, the 50 minute dose achieved positive treatment effect on the upside of our target and replicates the results in our 2a study (executed in the U.S. in similar gesta

  22. Slide 22: AEROSURF Phase 2b Q&A

    AEROSURF® Phase 2b Q&A 2

Windtree Therapeutics — Corporate Update (June 2017) on 6ix